NDAORALTABLETPriority Review
Approved
Feb 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UKONIQ (umbralisib tosylate) is an oral small-molecule PI3K delta inhibitor approved by the FDA in February 2021. It is indicated for certain hematologic malignancies and operates through inhibition of phosphatidylinositol 3-kinase delta signaling in B-cell populations. The drug represents a targeted therapy approach for patients with relapsed or refractory disease.
Peak8.6 years to LOE
Product is in peak commercial phase with established market presence; brand teams managing mature commercial operations with focused specialty/hematology-oncology field presence.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on UKONIQ positions professionals in TG Therapeutics' oncology/hematology franchise during a stable peak-revenue phase. Roles emphasize specialty market expertise, payer relationships, and disease state management in a niche but established indication.
Brand ManagerMedical Science Liaison (Oncology/Hematology)
Worked on UKONIQ at TG Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.